Hogg et al. demonstrated that the inhibition of PDCD1L1 transcription by the BET inhibitor is independent of MYC expression, which is usually involved in PD-L1 expression regulation and is also as a target for BET inhibitors in hematologic malignancies (102, 103). Here, CD274 is linked to hematologic disorder.